Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma

Yue,Xiaoni; Utsunomiya,Hiroki; Akahira,Jun-Ichi; Suzuki,Fumihiko; Ito,Kiyoshi; Nagase,Satoru; Sasano,Hironobu; Yaegashi,Nobuo

doi:10.3892/ol.2012.1094

Expression of steroid and xenobiotic receptor in uterine carcinosarcoma, leiomyosarcoma and endometrial stromal sarcoma

Authors:
- Xiaoni Yue
- Hiroki Utsunomiya
- Jun-Ichi Akahira
- Fumihiko Suzuki
- Kiyoshi Ito
- Satoru Nagase
- Hironobu Sasano
- Nobuo Yaegashi
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan, Department of Pathology, Graduate School of Medicine, Tohoku University, Sendai 980-8574, Japan
Published online on: December 28, 2012 https://doi.org/10.3892/ol.2012.1094
Pages: 835-839

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We analyzed the expression of the steroid and xenobiotic receptor (SXR) in human uterine sarcomas and evaluated its clinical significance. Forty-seven cases with archival specimens were examined for SXR expression using immunohistochemistry. All cases were scored using a semi-quantitative histological scoring (HSCORE) method. Specimens with a HSCORE >40 were regarded as SXR-positive. Various clinicopathological variables, including the expression status of estrogen receptor (ER)-α, progesterone receptor (PR) and Ki67 (MIB-1) were examined. The mean SXR HSCOREs of carcinosarcoma (CS) and leiomyosarcoma (LMS) were 9.13 and 23.6, respectively, and SXR-positive rates were 3 out of 24 (12.5%) and 4 out of 17 (23.5%), respectively. SXR was not detected in endometrial stromal sarcoma (ESS). In CS cases, significant differences were detected between the expression of SXR and age and disease stages. There was no significant correlation between SXR-positive status and either disease-free survival or overall survival. Our results support an association between SXR and malignant behavior. Our results show that overexpression of SXR may represent a useful marker to identify patients with advanced-stage CS. In addition, our results showed that SXR may aid in the diagnosis of uterine sarcomas.

View Figures

View References

1	Akahira J, Tokunaga H, Toyoshima M, et al: Prognoses and prognostic factors of carcinosarcoma, endometrial stromal sarcoma and uterine leiomyosarcoma: a comparison with uterine endometrial adenocarcinoma. Oncology. 71:333–340. 2006. View Article : Google Scholar
2	Curtin JP, Blessing JA, Soper JT, et al: Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 83:268–270. 2001. View Article : Google Scholar : PubMed/NCBI
3	Thigpen T, Blessing JA, Beecham J, et al: Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a gynecologic oncology group study. J Clin Oncol. 9:1962–1966. 1991.PubMed/NCBI
4	Takara K, Takagi K, Tsujimoto M, et al: Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun. 306:116–120. 2003. View Article : Google Scholar : PubMed/NCBI
5	Miki Y, Suzuki T, Tazawa C, et al: Steroid and xenobiotic receptor (SXR), cytochrome P450 3A4 and multidrug resistance gene 1 in human adult and fetal tissues. Mol Cell Endocrinol. 231:75–85. 2005. View Article : Google Scholar : PubMed/NCBI
6	Gupta D, Venkatesh M, Wang H, et al: Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res. 14:5332–5340. 2008. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Huang H, Li H, et al: Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res. 13:2488–2495. 2007. View Article : Google Scholar : PubMed/NCBI
8	Masuyama H, Hiramatsu Y, Kodama J, et al: Expression and potential roles of pregnane X receptor in endometrial cancer. J Clin Endocrinol Metab. 88:4446–4454. 2003. View Article : Google Scholar : PubMed/NCBI
9	Miki Y, Suzuki T, Kitada K, et al: Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A in human breast carcinoma. Cancer Res. 66:535–542. 2006. View Article : Google Scholar : PubMed/NCBI
10	Masuyama H, Nakatsukasa H, Takamoto N, et al: Down-regulation of pregnane X receptor contributes to cell grown inhibitor and apoptosis by anticancer agents in endometrial cancer cells. Mol Pharmacol. 72:1045–1053. 2007. View Article : Google Scholar : PubMed/NCBI
11	Staudinger JL, Goodwin B, Jones SA, et al: The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci USA. 98:3369–3374. 2001. View Article : Google Scholar
12	Xie W, Barwick JL, Downes M, et al: Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature. 406:435–439. 2000. View Article : Google Scholar : PubMed/NCBI
13	Masuyama H, Suwaki N, Tateishi Y, et al: The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol Endocrinol. 19:1170–1180. 2005. View Article : Google Scholar : PubMed/NCBI
14	Yue X, Akahira J, Utsunomiya H, et al: Steroid and xenobiotic receptor (SXR) as a possible prognostic marker in epithelial ovarian cancer. Pathl Int. 60:400–406. 2010. View Article : Google Scholar : PubMed/NCBI
15	Sasano H, Frost AR, Saitoh R, et al: Aromatase and 17β-hydroxysteroid dehydrogense type 1 in human breast carcinoma. J Clin Endocrinol Metab. 81:4042–4046. 1996.
16	Masuyama H, Hiramatsu Y, Mizutani H, et al: The expression of pregnane X receptor and its target gene, cytochrome P450 3A1 in perinatal mouse. Mol Cell Endocrinol. 172:47–56. 2001. View Article : Google Scholar : PubMed/NCBI
17	Blumberg B, Sabbagh W Jr, Juguilion H, et al: SXR, a novel and xenobiotic-sensing nuclear receptor. Genes Dev. 12:3195–3205. 1998. View Article : Google Scholar : PubMed/NCBI
18	Suzuki T, Moriya T, Sugawara A, et al: Retinoid receptor in human breast carcinoma: possible modulators of in situ estrogen metabolism. Breast Cancer Res Treat. 65:31–40. 2001. View Article : Google Scholar : PubMed/NCBI
19	Toyoshima M, Akahira J, Matsunaga G, et al: Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol. 94:774–778. 2004. View Article : Google Scholar : PubMed/NCBI
20	Dotzlaw H, Leygue E, Watson P, et al: The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin Cancer Res. 5:2103–2107. 1999.PubMed/NCBI